Abstract
Although improvements in surgery and radiotherapy have also occurred, National Cancer Institute data from 2.1 million patients with cancer in the USA between 1975 and 1995 have led to the conclusion that “cancer-fighting drugs improved survival rates, especially for cancer of the prostate, where drug innovations have been the greatest” [1]. In prostate cancer, the most important drugs have been gonadotropinreleasing hormone (GnRH) agonists [2] and pure anti-androgens permitting the administration of a pure anti-androgen combined with medical or surgical castration (combined androgen blockade [CAB]), at the start of treatment [3]. However, despite significant improvements in diagnosis and treatment, prostate cancer remains the second most common cause of death after lung cancer in American men.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
